IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer

NCT07402070 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Resectable Stage II-III Non-small Cell Lung Cancer

Interventions

DRUG: IBI363

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.